Systems and methods for non-invasively monitoring hemoglobin
Monitoring hemoglobin concentration through non-invasive optical methods, using adhesion or plug-in equipment and remote center analysis, the problem that traditional blood tests cannot monitor hemoglobin for a long time is solved, and the continuous tracking of hemoglobin concentration and timely detection of acute conditions is achieved, improving the Diagnostic efficiency.
Patent Information
- Application Number
- CN201980007665.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2019-01-11
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2039-05-18
AI Technical Summary
The prior art is difficult to monitor hemoglobin concentrations for a long time, and traditional blood tests require blood draw, and it is impossible to track changes in hemoglobin levels in real time or in long term, especially when monitoring chronic or acute conditions, there is a lack of effective tools.
Using a non-invasive approach, monitoring the first and second emission responses by providing a specific wavelength of incident light to the patient tissue, calculating hemoglobin concentrations, continuously monitoring using an adhesion, pluggable or wearable device, and through gateways and remote centers Perform data analysis and reporting.
Long-term monitoring of hemoglobin concentration and timely detection of acute conditions are achieved, which reduces the time cost of laboratory examinations, allows continuous collection of physiological data in daily life, and improves the accuracy and efficiency of diagnosis.
Smart Images

Figure CN111683597B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates generally to patient diagnosis and monitoring, and particularly to non-invasively diagnosing and monitoring hemoglobin concentration. Background Art
[0002] Hemoglobin (Hb) is an iron-containing protein present in the blood, and hemoglobin is a component responsible for transporting gases (such as oxygen and carbon dioxide) throughout the body. Measuring hemoglobin concentration is a useful tool when screening patients for diseases such as anemia. Usually, hemoglobin concentration measurement requires collecting blood samples from patients, and blood samples are sent to laboratories for analysis to separate and measure the concentration of hemoglobin in the patient's blood. It usually takes 1-2 days to obtain the result, and the result is based on the hemoglobin level of the patient when drawing blood. Therefore, this is not feasible for continuously monitoring hemoglobin levels in long periods of time.
[0003] Therefore, it would be advantageous to develop a device that could detect and chronically monitor hemoglobin concentration (as well as other blood components such as hematocrit, HbA1C, advanced glycation end (AGE) products), which would allow detection of acute conditions as well as chronic conditions that change slowly over time. Summary of the invention
[0004] A method for non-invasively monitoring hemoglobin concentration includes providing incident light at a first excitation wavelength to patient tissue. The method further includes: monitoring a first emission response at a first emission wavelength, wherein the first emission wavelength is selected to correspond to a maximum or dominant wavelength of the emission response; and monitoring a second emission response at a second emission wavelength, wherein the second emission wavelength is selected to correspond to a minimum or significant wavelength of the emission response. The hemoglobin concentration is calculated based on a ratio of the first emission response to the second emission response. BRIEF DESCRIPTION OF THE DRAWINGS
[0005] Figure 1 A schematic diagram of a patient and a patient monitoring system is shown in accordance with some embodiments.
[0006] Figure 2A-2C is a perspective view of an adhesion monitoring device according to some embodiments.
[0007] Figure 3 is a perspective view of an insertable monitoring device according to some embodiments.
[0008] Figure 4 is a block diagram illustrating components for monitoring optical signals and processing optical signals according to some embodiments.
[0009] Figure 5is a flow chart illustrating steps for measuring hemoglobin concentration according to some embodiments.
[0010] Figure 6 is a graph showing the relative absorbance of hemoglobin at various wavelengths and the minimum and maximum wavelengths for measuring hemoglobin concentration according to some embodiments.
[0011] Figure 7 is a flow chart illustrating steps for measuring hemoglobin concentration by utilizing isosbestic wavelengths according to some embodiments.
[0012] Figure 8 is a graph showing the relative absorbance of hemoglobin at various wavelengths and the significant wavelength using the isosbestic wavelength as the maximum wavelength for both oxyhemoglobin and deoxyhemoglobin according to some embodiments.
[0013] Fig. 9 is a flow chart illustrating steps for measuring hemoglobin concentration using two light sources and a single detector according to some embodiments.
[0014] Fig.10 is a flow chart illustrating long-term monitoring and storage of hemoglobin concentration and one or more physiological signals for detecting a patient condition, according to some embodiments.
[0015] Fig.11 is a flow chart illustrating dynamic monitoring and storage of hemoglobin concentration and one or more physiological signals for detecting a patient condition according to some embodiments. DETAILED DESCRIPTION
[0016] Figure 1 A patient P and a monitoring system 10 for non-invasively monitoring blood concentration levels (e.g., hemoglobin, oxyhemoglobin, deoxyhemoglobin, etc.) are shown. Figure 1 In the embodiment shown in FIG. 1 , the monitoring system 10 includes patient medical devices 100 and / or 110, a gateway 102, and a remote monitoring center 106. Figure 1 In the embodiment shown in , the patient medical device 100 is an adhesive device attached to the patient's skin, and the patient medical device 110 is a clip that fits on the patient's finger. In other embodiments, the patient medical device may include an implantable device, an insertable device, an injectable device and / or a wearable device, such as a Holter monitor (collectively referred to as a medical device). In each example, the patient medical device utilizes an optical component to monitor the patient's blood concentration level. In some embodiments, the patient medical device 100 includes one or more additional sensors for monitoring one or more additional physiological parameters of the patient, such as activity, orientation, cardiac activity, hydration, etc.
[0017] exist Figure 1 In the embodiment shown in , the medical device 100 is adhered to the chest T of the patient P, which allows for monitoring of additional physiological parameters, such as ECG, hydration, activity, etc. In many embodiments, the device can be adhered to one side of the patient, from which data can be collected. The benefit of using an adhered device, an implantable, an injectable and / or a wearable device is that it can be used to collect physiological data from the patient while the patient is performing normal daily activities outside of a hospital environment. A medical device (such as medical device 110) clipped to a patient's finger is not worn by the patient all day, but may be useful in some applications, such as those applications where it is relatively simple to apply the clip to the patient's finger in order to collect readings. That is, rather than the patient wearing the device for an extended period of time, the patient can periodically clip the device to the patient's finger for a few moments (e.g., a few seconds) to non-invasively measure blood concentration levels (e.g., oxyhemoglobin, deoxyhemoglobin), and then remove it.
[0018] As discussed above, in some embodiments, the medical device may monitor multiple physiological parameters associated with the patient P, including optical signals for determining blood concentration levels, electrocardiogram (ECG) signals for detecting rhythm abnormalities (such as tachycardia and / or bradycardia), and activity level data, posture, bioimpedance, etc. One or more of these physiological parameters may be analyzed locally by the medical device 100 or 110, or remotely by the gateway 102 and / or the remote monitoring center 106 (or a similar platform separate from the local medical device 100). In one embodiment, the gateway 102 is a stand-alone device that is typically installed in the patient's home. In other embodiments, the gateway 102 may be a patient device (such as a smart phone, tablet, or computer) that is capable of storing and executing one or more applications that are designed to process signals received from the medical device 100 and / or 110. Non-invasive monitoring of blood concentration levels relies on one or more optical sensors positioned on a medical device to provide an excitation source (e.g., light) to patient tissue and monitor the emission response (e.g., light emitted by patient tissue due to reflection, fluorescence, or absorption of incident light). For example, in one embodiment, one or more light sources associated with the medical device direct incident light to patient tissue. In addition, one or more photodetectors associated with the medical device receive light emitted from the patient at a specific emission wavelength associated with the photodetector (e.g., a wavelength of 590 nm). The photodetector converts the measured emission (i.e., optical signal) into an electrical signal representing the amplitude or intensity of the emitted light. As discussed in more detail below, analysis of the detected optical signal can be used to monitor blood concentration levels. In some embodiments, analysis is performed locally by the medical device 100 or 110, while in other embodiments, the monitored optical signal is transmitted to the gateway 102 or the remote center 106 for analysis to detect blood concentration levels.
[0019] In one embodiment, gateway 102 includes zLink TM Components, zLink TMIt is a small portable device similar to a mobile phone that wirelessly transmits information received from the medical device 100 to the remote monitoring center 106. The gateway 102 may be composed of multiple devices that can communicate with the remote center 106 by wire or wirelessly in a variety of ways, for example, using a connection 104 that may include an Internet connection and / or using a cellular connection. The remote center 106 may include a hosting application for data analysis and storage, which also includes a website that enables secure access to physiological trends and clinical event information for interpretation and diagnosis. The remote center 106 may further or alternatively include back-end operations, where the physiological data from the adhered device 100 or 110 is read by a human expert to verify accuracy. A report may then be generated at the remote monitoring center 106 for transmission to the patient's physician or caregiver. As discussed above, in other embodiments, the gateway 102 may be implemented using a user device, such as a smart phone, tablet, or computer, which is capable of storing and executing one or more applications that are capable of processing data received from the medical devices 100 and / or 110 and transmitting the received data to the remote monitoring center 106.
[0020] In an exemplary embodiment, the monitoring system includes a distributed processor system having at least one processing module (not shown) included as part of the adherent device 100, at least one processor 102P of the gateway 102, and at least one processor 106P at the remote center 106, each of which can be in electronic communication with the other processors. At least one processor 102P includes a tangible medium 102T, and at least one processor 106P includes a tangible medium 106T. The remote processor 106P may include a back-end server located at the remote center. The physiological parameters (including optical signals) monitored by the medical device 100 may be analyzed by one or more of the distributed processors included as part of the medical device 100, the gateway 102, and / or the remote monitoring center 106.
[0021] Figure 2A-2C is a perspective view of an adhesive monitoring device according to some embodiments. The adhesive device is adhered to the patient's skin and includes one or more sensors for monitoring the patient's physiological parameters. Adhesive devices are typically used for long-term monitoring of outpatients, allowing the patient's physiological parameters to be monitored over a period of time (e.g., days, weeks, months). The adhesive device thus allows long-term monitoring of patients with chronic conditions (e.g., anemia) as well as monitoring and detecting both acute onsets (e.g., carbon monoxide poisoning). This is in contrast to typical blood tests, which require blood to be drawn by a laboratory and thus do not allow for long-term monitoring or detection of acute conditions.
[0022] Figure 2A The adherent device 200 shown in FIG. 2 shows a relatively low height profile of the adherent device, which allows the patient to comfortably wear the device for a longer period of time.
[0023] exist Figure 2B In the embodiment shown in , the bottom surface 202 of the adhesive device 200 is shown, which includes a plurality of electrodes 204a-204d, at least one light emitter 206, and two light detectors 208a, 208b. The electrodes 204a-204b are used to monitor electrical activity associated with the patient, including monitoring electrocardiogram (ECG) information and bioimpedance. At least one light emitter 206 is used to generate an excitation signal (e.g., incident light) provided to the patient's tissue. The light provided by the light emitter 206 may be composed of multiple wavelengths, including visible light, ultraviolet light (wavelength shorter than visible light) and infrared light (wavelength longer than visible light). In other embodiments, the light provided by the light emitter 206 may be composed of one or more selected wavelengths. Depending on the particular aspect / component of the blood to be monitored (e.g., hemoglobin, oxyhemoglobin, deoxyhemoglobin, glycosylated hemoglobin A1c (HbA1c), hematocrit level, etc.), different wavelengths of light may be selected so as to generate a particular emission response, which refers to how incident light at a particular wavelength interacts with the blood component via reflection, absorption, fluorescence, etc., which is represented by the light emitted from the patient. For example, hemoglobin is defined by an emission response to incident light provided at a particular wavelength.
[0024] In addition, if Figure 2B In the embodiment shown in FIG. 1 , the bottom surface 202 of the adhesive device 200 includes two or more light detectors 208a, 208b. In this embodiment, each light detector is configured to detect light at a specific emission wavelength. The wavelength selected is based on the emission response or morphology of the blood component being analyzed (e.g., hemoglobin, hematocrit, platelets, etc.). In a laboratory environment, the entire spectral response (e.g., all wavelengths) can be measured and analyzed. However, in an adhesive device, the cost of doing so is also prohibitive. Instead of monitoring all wavelengths, Figure 2BThe embodiment shown in selects two or more wavelengths to monitor. The wavelength is selected based on the specific blood component being analyzed, and the wavelength is selected to be associated with at least one maximum and at least one minimum of the emission response. Alternatively, the emission wavelength may be selected to reflect a significant wavelength from the absorbance spectrum of hemoglobin. For example, hemoglobin is defined by a spectral response that includes a maximum at a wavelength of about 575nm and a minimum at a wavelength of about 560nm. In this example, the photodetector 208a may be configured to monitor the properties (e.g., amplitude) of the emission response provided at 575nm, and the photodetector 208b may be configured to monitor the properties (e.g., amplitude) of the emission response provided at 560nm.
[0025] Based on the measured properties of the light emitted at the selected wavelengths, a ratio of the measured properties is calculated, wherein the ratio provides a measure of the blood concentration component. The benefit of using a ratio is that the measurement is relatively immune to noise and external factors, such as changes in ambient light intensity, molecular concentrations, artifacts, light source instability, detector instability, and / or changes in sensor placement. For example, measurements collected at night (when little or no external light is available) may provide much lower amplitudes than those measured when the patient is outdoors in the sun, where the light from the sun enhances the amplitudes measured at both the minimum and maximum values.
[0026] Despite Figure 2B In the embodiment shown in FIG. 1 , a single light emitter 206 is shown with a pair of detectors 208a and 208b, but in other embodiments, multiple light emitters may be utilized with more than two detectors. In addition, although each light emitter and detector are shown as separate entities, in some embodiments, the functionality of the light emitter and detector are included in a single device. Therefore, in one embodiment, a light detector 208 may also be included on the light source 206. The light detector may be implemented using a well-known imaging sensor (such as a CCD or CMOS image sensor).
[0027] Figure 2B The number of detectors 208 is greater than the number of light emitters 206, and Figure 2B In contrast to the embodiment shown in FIG. 1 , in other embodiments, the number of light emitters 206 may be greater than the number of detectors 208. For example, in Figure 2CIn the embodiment shown in , instead of utilizing a single light source or emitter and two or more detectors, the adhered device 210 includes a pair of emitters 212a and 212b and a single light detector 214. In this embodiment, each light source or emitter 212a and 212b provides incident light at a unique wavelength. The light detector 214 monitors emission at a single wavelength, which is selected to correspond to the emission response associated with the first excitation wavelength and the emission response associated with the second excitation wavelength.
[0028] In some embodiments, light emitters 212a and 212b are controlled to generate incident light that is mutually exclusive of each other (e.g., one at a time). This allows detector 214 to separately measure the emission response associated with the first excitation wavelength and the emission response associated with the second excitation wavelength. For example, in one embodiment, light emitter 212a is activated to provide incident light at a first wavelength. Light detector 214 measures properties (e.g., amplitude) of the emission response at a given emission wavelength. Subsequently, light emitter 212a is disabled and light emitter 212b is activated to provide incident light at a second wavelength. Light detector 214 measures properties (e.g., amplitude) of the emission response at the same given emission wavelength. The ratio of the measured amplitudes is used to measure blood concentration components (e.g., hemoglobin).
[0029] In other embodiments, more than two light sources (e.g., light emitters) may be used to provide incident light at more than two unique wavelengths. In addition, more than a single photodetector may be utilized to facilitate measuring properties of emission responses at multiple emission wavelengths. Similarly, although in Figure 2C In the embodiment, a pair of light emitters 212a and 212b and a single light detector 214 are utilized. In other embodiments, more than two light emitters can be utilized with multiple light detectors. In addition, although each light emitter and light detector are shown as separate entities, in some embodiments, the functions of the light emitter and light detector are included in a single element.
[0030] Figure 3300 is a perspective view of an insertable monitoring device 300 according to some embodiments. In contrast to an adhesive device that is fixed to the patient's skin, the insertable monitoring device 300 is inserted subcutaneously. The insertable device 300 includes at least a first electrode 302a and a second electrode 302b, at least one light emitter 304, and at least one light detector 308. As discussed above, in order to generate a desired ratio, at least two light emitters 304 are required in combination with at least one detector 308, or at least two light detectors 308 are required in combination with at least one light emitter 304. For example, in one embodiment, the insertable monitoring device 300 utilizes first and second light detectors, each of which measures a property at a unique emission wavelength, and at least one light emitter provides light at a desired excitation wavelength. In this embodiment, the emission wavelengths selected for the first and second light detectors 308 are based on the specific blood components being analyzed and are selected to be associated with at least one maximum and at least one minimum of the emission response of the monitored component. For example, oxygenated hemoglobin is defined by an emission response that includes a maximum at a wavelength of about 575nm and a minimum at a wavelength of about 560nm. In one embodiment, the first light detector 308 may be configured to monitor the amplitude of light provided at 575 nm, and the second light detector 308 may be configured to monitor the amplitude of light provided at 560 nm.
[0031] Likewise, in another embodiment, the insertable monitoring device 300 utilizes two or more light emitters (i.e., in addition to the light emitter 304, a second light emitter is also utilized) and at least one light detector 308. In this embodiment, the first light emitter provides light at a first excitation wavelength, and the second light emitter provides light at a second excitation wavelength. The first and second light emitters are controlled so that incident light is provided at different times. For example, the first light emitter may generate incident light for a first time period, and the second light emitter may generate incident light for a second time period after the first time period. The light detector 308 measures one or more properties associated with the emission response at each of the excitation wavelengths. A ratio is calculated based on the measured properties, and the ratio is used to determine the expected ratio, which is used to determine the blood component concentration. The benefit of utilizing the ratio is that the placement of the insertable device may affect the amplitude of the measured properties. For example, placement on a vein may increase the absolute value of the measured properties. By utilizing the ratio, the change in the absolute value based on placement is reduced.
[0032] Figure 4 is a block diagram illustrating components for monitoring optical signals and processing optical signals according to some embodiments.
[0033] Medical device 400 includes at least one light source 402, at least one detector 404, filter / amplifier 406, processor / microcontroller 408, memory 410 and communication / output 412. As described above, medical device 400 can be adhered to the patient's skin, clamped on the patient's finger, attached via an arm cuff, inserted subcutaneously or implanted in the patient's body. Light source 402 emits light, which is provided to be incident on the patient's tissue, which is referred to as "excitation" herein. In some embodiments, excitation at multiple wavelengths or selected wavelengths can be provided. For example, the wavelength of the emitted light can be selected based on the blood component to be analyzed (e.g., a specific protein), wherein light of different wavelengths interacts with the specific protein in different ways. In some embodiments, light source 402 includes multiple light sources, each of which is capable of emitting at a specific unique wavelength.
[0034] Light from light source 402 interacts with patient tissue 414 or patient fluids, proteins, or photosensitized molecules. The interaction is the result of one or more processes, including autofluorescence, absorption, transmission, and reflection, which results in light emission from the tissue, referred to as an emission response. The emission response is detected by one or more light detectors 404, which may be placed near light source 402 (e.g., Figure 2B , Figure 2C and Figure 3 ) or placed on the opposite side of the patient's tissue, which is common in pulse oximeters. In some embodiments, the light detector 404 may utilize a well-known optical sensor, such as a complementary metal oxide semiconductor (CMOS) sensor or a charge coupled device (CCD) sensor. Each of the one or more light detectors 404 is configured to detect light at a specific emission wavelength. For embodiments that monitor multiple emission wavelengths, multiple light detectors 404 are required, each configured to monitor one of the desired emission wavelengths. The emission wavelength monitored by one or more light detectors 404 is selected based on the specific blood component being monitored. For example, the emission response morphology (i.e., the amplitude of the emission response across the entire wavelength spectrum) depends on how the light interacts with the monitored blood component, where the emission response of each blood component provides a different emission response morphology. Specifically, the emission wavelength monitored by one or more light detectors is selected to correspond to the maximum and / or minimum values associated with the monitored emission response spectrum, or to one or more significant wavelengths on the emission spectrum.
[0035] The one or more photodetectors convert the monitored optical signal (ie, emission response) into an electrical signal representative of the amplitude of the monitored emission wavelength. The filter / amplifier 406 filters and amplifies the signal to provide a clean signal to the processor / microprocessor 408.
[0036] The processor / microcontroller 408 operates in conjunction with the memory 410 and the communication output 412. In some embodiments, the processor / microcontroller 408 provides the measured emission response signal monitored by the light detector to the intermediate gateway 102 and / or the remote monitoring center 106 (at Figure 1 ) for subsequent processing. In other embodiments, the processor / microcontroller 408 locally executes instructions for performing analysis of the monitored emission responses. This may include: calculating a ratio associated with two or more monitored emission responses; calculating a blood component concentration based on the calculated ratio; comparing the ratio and / or blood component concentration to a threshold; and / or storing the calculated ratio and / or blood component concentration to the memory 410. The results of any analysis performed locally by the processor / microcontroller may then be transmitted to the intermediate device 102, the gateway 106, or provided to the patient as an alarm (e.g., an audio alarm).
[0037] Figure 5 is a flow chart illustrating steps for measuring hemoglobin concentration according to some embodiments. Figure 6 , Figure 6 600) and the relative absorbance of deoxygenated hemoglobin (line 602) at various wavelengths according to some embodiments, as well as the minimum and maximum wavelengths for measuring hemoglobin concentration. The change in relative absorbance is a result of changes in the molecular structure when oxygen molecules are attached to hemoglobin versus when there are no oxygen molecules attached. A typical pulse oximeter utilizes a wavelength at which the relative absorbance of oxyhemoglobin and deoxyhemoglobin differ significantly, and utilizes the measured amplitude to determine the concentration of oxyhemoglobin relative to deoxyhemoglobin. For example, at a wavelength of about 660 nm ( Figure 6 ), the relative absorbance between oxyhemoglobin and deoxyhemoglobin is significantly different. Measuring the amplitude of the light emitted at 660 nm and measuring the amplitude of the emitted light allows a determination to be made regarding the concentration of oxyhemoglobin and / or deoxyhemoglobin. However, as an absolute measurement, the measurement is very susceptible to noise and external influences. For example, changes in the ambient light level will affect the measured amplitude, resulting in errors in the measurement. In contrast, the present invention utilizes the minimum and maximum values in the known emission response to generate one or more ratios, as discussed in more detail below.
[0038] At step 500, one or more light sources are used to illuminate patient tissue at one or more excitation wavelengths. In one embodiment, the light source is provided at a wavelength selected based on the blood concentration component to be measured. For example, the wavelength is typically selected in the ultraviolet (UV) spectrum, the visible spectrum, or the infrared (IR) spectrum so as to generate an absorbance, reflection, transmission, and / or fluorescence response (i.e., an emission response) having a desired spectral shape. Figure 5 and Figure 6 In the embodiment shown in , light is provided at a single excitation wavelength (eg, red visible light, infrared light), but in other embodiments, light may be provided at multiple wavelengths (eg, visible white light).
[0039] In response to excitation provided by the light source, an emission response is generated that is, at least in part, a function of the concentration of oxyhemoglobin and deoxyhemoglobin in the patient's tissue. Figure 6 A full spectral sweep of each of the wavelengths shown in and measurement of the resulting emission response is one method for determining the concentration of oxyhemoglobin and deoxyhemoglobin, but as discussed above, this is prohibitive in terms of computational and battery power requirements. To overcome the cost issue of a full spectral wavelength sweep for measuring the concentration levels of various blood components, wavelength measurement is limited to monitoring two emission wavelengths.
[0040] At step 502, first and second photodetectors measure emission at a first wavelength λ1 and a second wavelength λ2, respectively. The first emission wavelength λ1 is selected to correspond to a known maximum of the emission response. Figure 6 In the embodiment shown in FIG. 1 , the maximum associated with oxygenated hemoglobin occurs at about λ1 (e.g., a wavelength of 578 nm). The second emission wavelength λ2 is selected to correspond to a known minimum in the emission response of oxygenated hemoglobin. For example, at Figure 6 In the embodiment shown in , the minimum associated with oxyhemoglobin occurs approximately at any wavelength greater than 620 nm (e.g., 640 nm is selected in this embodiment). If deoxyhemoglobin is to be monitored, emission wavelengths corresponding to the maximum and minimum values of the deoxyhemoglobin emission response are selected. For example, an emission wavelength λ3 corresponding to the maximum value of the deoxyhemoglobin emission response (e.g., a wavelength of approximately 555 nm) and a second emission wavelength λ4 corresponding to the minimum value of the deoxyhemoglobin emission response (e.g., a wavelength greater than approximately 640 nm, a wavelength of 650 nm is utilized in this embodiment) are selected. In some embodiments, the minima associated with oxyhemoglobin and deoxyhemoglobin may utilize the same emission wavelength (e.g., a wavelength of 640 nm).
[0041] The measurements collected at step 502 are measurements of properties of the emission response (e.g., intensity, amplitude, phase, etc.). Generally speaking, a light detector responsible for measuring a property at a particular emission wavelength converts the detected light into an electrical signal representative of the measured property. Figure 6In the embodiment shown in , the measured amplitude is analyzed based on relative absorbance spectroscopy, but one or more other processes that affect the light emission from the tissue in response to the incident light may be considered. In general, the concentration of blood at any particular time is a combination of oxyhemoglobin and deoxyhemoglobin, such that the measured amplitude is a combination of the absorbance produced by the oxyhemoglobin concentration and the deoxyhemoglobin concentration. At a selected minimum wavelength (e.g., λ2), both oxyhemoglobin and deoxyhemoglobin exhibit relatively low absorbance. In contrast, at a selected maximum wavelength (e.g., λ1), oxyhemoglobin and deoxyhemoglobin exhibit a large difference in relative absorbance. This difference in relative absorbance is required in order to determine the relative concentration levels of oxyhemoglobin and deoxyhemoglobin using the measured amplitude. For example, the amplitude of the emission response at wavelength λ1 will decrease as the concentration of oxyhemoglobin increases because there is a difference in the relative absorbance of oxyhemoglobin and deoxyhemoglobin at this wavelength, with oxyhemoglobin exhibiting a greater relative absorbance. However, the emission response at wavelength λ1 will also decrease in response to changes in environmental conditions, such as a patient walking from an outdoor environment to an indoor environment, which cannot be known simply by measuring the raw amplitude at a particular wavelength, resulting in an erroneous determination of oxyhemoglobin. In order to account for this change in absolute amplitude in response to external conditions (e.g., ambient light conditions), one or more ratios are utilized. Other factors that may introduce errors into the absolute raw amplitude include body movement, muscle flexion and extension, circulatory perfusion, movement of incident light relative to patient tissue, etc.
[0042] At step 504, one or more ratios R (eg, R1 = λ1 / λ2) are calculated based on the measured emissions at the first and second wavelengths λ1 and λ2. Figure 1 The calculated ratio may be calculated on an intermediate device 102 (such as Figure 1 The calculated ratio is measured at a remote monitoring center 106 (as shown in Figure 1 The calculated ratio is measured remotely at a location (shown in FIG. 1 ) of FIG. 1 . The benefit of using the ratio R relative to using an absolute measurement at a specific emission wavelength is that using the ratio R reduces the effect of noise on the measured blood concentration. For example, by using the ratio of the maximum to the minimum value, the effect of changes in ambient light (which also interacts with the patient's tissue) is eliminated. For example, at Figure 6 In the embodiment shown in which oxyhemoglobin is monitored, the ratio R can be calculated based on the amplitude measured at wavelength λ1 divided by the amplitude measured at wavelength λ2. Changes in ambient light reduce the amplitude of the emission response at wavelength λ1 and similarly and proportionally reduce the amplitude of the emission response at wavelength λ2.
[0043] In one embodiment, the ratio R is defined as the amplitude measured at wavelength λ1 divided by the amplitude measured at wavelength λ2 (eg, R=A λ1 / A λ2 ). As the concentration of oxyhemoglobin increases, the amplitude measured at wavelength λ1 decreases in response to the higher absorption of the increased oxyhemoglobin concentration. As deoxyhemoglobin absorbs more light at wavelength λ2, the amplitude measured at wavelength λ2 may increase slightly, however, the relative absorbance of either oxyhemoglobin or deoxyhemoglobin at wavelength λ2 is quite low, and therefore the amplitude measured at wavelength λ2 will remain relatively unchanged. The net result is that the ratio R decreases in response to increasing oxyhemoglobin concentration. In addition, changes in ambient light do not result in significant changes in the ratio R result. For example, if a patient moves from outdoors (e.g., a sunny environment) to indoors, the corresponding decreases in the measured amplitudes at wavelengths λ1 and λ2 are relatively the same, which allows the ratio to remain relatively constant under changing environmental conditions.
[0044] In other embodiments, various other ratios R may be calculated based on the measured emission wavelengths. For example, the ratio may be defined as the amplitude (maximum) measured at wavelength λ3 to the amplitude (minimum) measured at wavelength λ4, which provides information about the deoxyhemoglobin concentration level. In other embodiments, the ratio may be defined as the amplitude (maximum of oxyhemoglobin) measured at wavelength λ1 to the amplitude (maximum of deoxyhemoglobin) measured at wavelength λ3 to provide a ratio of the oxyhemoglobin concentration level to the deoxyhemoglobin concentration level.
[0045] At step 506, the calculated ratio R is used to determine the blood component concentration level (e.g., oxygenated hemoglobin concentration, deoxygenated hemoglobin concentration, etc.). In one embodiment, the concentration level can be associated with various ratios R. For example, the medical device (or remote monitoring device) can include a stored table that associates the measured ratios with the concentration levels. In other embodiments, multiple ratios can be used to determine the concentration level. For example, in Figure 6 In the embodiment shown in , a first ratio R1 can be calculated based on the maximum / minimum values associated with oxygenated hemoglobin, and a second ratio R2 can be calculated based on the maximum / minimum values associated with deoxyhemoglobin. Multiple ratios can be used alone or in combination with each other to determine concentration levels. For example, a combination of ratios R1 and R2 can be used to determine the total concentration of hemoglobin (e.g., a combination of oxygenated hemoglobin and deoxyhemoglobin).
[0046] In one embodiment, a medical device (e.g., Figure 1 and Figure 2A-2C The adhesion devices 100, 200, Figure 1 The monitoring clip 110 shown in Figure 3 In some embodiments, the determination of the concentration level of one or more blood components is performed locally (such as the insertable device 300 shown in FIG. 1 ). In other embodiments, the measured amplitude and / or ratio is transmitted to an intermediate device and / or a remote monitoring center, and the determination of the concentration level is performed by the intermediate and / or remote monitoring center.
[0047] At step 508, the determined concentration level is stored and / or analyzed for use in detecting a patient condition. For example, in one embodiment, the determined concentration level (e.g., hemoglobin concentration level) is compared to a threshold level to detect a condition such as anemia. In some embodiments, the threshold level is an absolute value, while in other embodiments, the threshold level is initialized relative to the patient. For example, to calculate the initialized value, the concentration level may be determined during an initial period (via optical monitoring or via a blood test). After the initial value is determined, a threshold level is determined based on the initial value, and the threshold level is used to detect a condition such as anemia.
[0048] In one embodiment, the storage of concentration levels and / or the comparison of concentration levels to threshold levels to detect patient conditions is performed locally on a medical device (e.g., an adherent device, an insertable device, etc.). In other embodiments, the storage of concentration levels and / or the comparison of concentration levels to threshold levels to detect patient conditions is performed remotely at an intermediate device and / or a remote monitoring center. In response to a detected condition, such as anemia and / or other hemoglobin-related conditions, an alarm or warning may be generated and transmitted to the patient and / or a monitoring party (e.g., a physician, a hospital, etc.).
[0049] exist Figure 5 and Figure 6 The benefit of the method described in is to provide the ability to monitor blood component concentration levels over a long period of time. Compared with typical laboratory tests that monitor concentration levels at the time of blood extraction, the present invention allows monitoring of concentration levels for long periods of time (e.g., days, weeks). The benefits of long-term monitoring include the ability to detect acute conditions throughout the monitoring period, and to provide patients with alerts of acute conditions to reduce the amount of time it takes for patients to receive a diagnosis. The benefits of long-term monitoring further include the ability to average concentration levels over a period of time to take into account changes in blood component concentration levels (which vary over a short timeframe based on the heartbeat of the patient concerned, and over a longer timeframe in response to the patient's condition). In addition, long-term monitoring allows detection and utilization of concentration trends to determine whether a condition is improving or worsening. For example, long-term monitoring can be used to monitor the efficacy of treatment, and / or to monitor the progression or deterioration of a condition.
[0050] Figure 7 is a flow chart illustrating steps for measuring hemoglobin concentration by utilizing isosbestic wavelengths according to some embodiments. Figure 7 is a graph showing the relative absorbance of hemoglobin at various wavelengths and the minimum of both the maximum wavelengths for oxyhemoglobin and deoxyhemoglobin using the isosbestic wavelength as the minimum according to some embodiments.
[0051] Generally speaking, Figure 7 and Figure 8 The embodiment shown in FIG. Figure 5 and Figure 6 The embodiments described are similar. The main difference is the choice of the emission wavelength minimum (eg, the emission wavelength corresponding to the emission response minimum). Figure 5 and Figure 6 Compared to the embodiment shown in Figure 7 and Figure 8 In the embodiment shown in FIG. 1 , the emission wavelength minimum is selected at an isosbestic point, which represents a point at which the total absorbance of the sample does not change during a chemical reaction or physical change of the sample. Figure 8 As shown in FIG. 8 , an isosbestic point exists at an emission wavelength λ5 (e.g., a wavelength of about 510 nm). At this isosbestic point, the emission response of oxyhemoglobin (line 800) and the emission response of deoxyhemoglobin (line 802) are both equal to each other. By using the isosbestic point as the emission wavelength minimum, a ratio can be calculated for monitoring only three emission wavelengths (rather than Figure 5 and Figure 6 ) to measure both oxyhemoglobin and deoxyhemoglobin.
[0052] At step 700, one or more light sources are used to illuminate the tissue at one or more excitation wavelengths. As discussed above, the excitation wavelength can be selected based on the blood component to be measured (i.e., the excitation wavelength is selected to generate an emission response with a desired morphology). To monitor blood component concentrations, the excitation wavelengths utilized are typically in the visible red spectrum or in the infrared spectrum. In other embodiments, light sources (e.g., white light) at multiple wavelengths are provided.
[0053] At step 702, one or more photodetectors are used to measure emission at a first wavelength λ5, a second wavelength λ6, and a third wavelength λ7. In some embodiments, only two emission wavelengths need be monitored in order to measure oxyhemoglobin or deoxyhemoglobin, but in this example, three emission wavelengths are monitored and utilized to measure two blood component concentrations. As discussed above, measuring the entire emission response (e.g., measuring at all wavelengths) is prohibitive. However, information about the concentration of the oxyhemoglobin blood component can be determined by measuring the emission response at the isosbestic wavelength λ5 and the second wavelength λ6. The first emission wavelength λ5 is selected to correspond to a significant wavelength of the emission response, which also corresponds to the isosbestic point between the oxyhemoglobin emission response and the deoxyhemoglobin emission response. For example, at Figure 8 In the embodiment shown in , the isosbestic point exists at an emission wavelength of about 510 nm. In addition to the isosbestic point, the second emission wavelength λ6 and the third emission wavelength λ7 are selected to correspond to the maximum values associated with the emission response of oxyhemoglobin and the emission response of deoxyhemoglobin. Figure 8 In the embodiment shown in , the maximum emission response associated with oxygenated hemoglobin occurs at wavelength λ6 (e.g., a wavelength of approximately 578 nm, or alternatively utilizing a local maximum at 540 nm), and the maximum emission response associated with deoxyhemoglobin occurs at wavelength λ7 (e.g., a wavelength of approximately 555 nm).
[0054] The measurement collected at step 702 is a measurement of the intensity / amplitude of the emission response. As discussed above, the light detector responsible for measuring the amplitude at a particular emission wavelength converts the detected light into an electrical signal representative of the measured amplitude. Figure 7 In the embodiment shown in , the measured amplitude is a measure of relative absorbance, but may be related to one or more other processes that result in luminescence from the tissue in response to incident light.
[0055] At step 704, one or more ratios R are calculated based on the measured emissions at the first wavelength λ5, the second wavelength λ6, and the third wavelength λ7. The first calculated ratio R1 is calculated based on the first wavelength λ5 and the second wavelength λ6, and provides information about the oxygenated hemoglobin concentration. The second calculated ratio R2 is calculated based on the first wavelength λ5 and the third wavelength λ7, and provides information about the deoxygenated hemoglobin concentration. As discussed above, utilizing isosbestic points allows for the calculation of ratios of both the oxygenated hemoglobin concentration and the deoxygenated hemoglobin concentration via monitoring of three emission wavelengths instead of four emission wavelengths.
[0056] At step 706, the calculated ratios R1 and R2 are used to determine two or more concentration levels (e.g., oxygenated hemoglobin concentration, deoxygenated hemoglobin concentration, etc.). In other embodiments, multiple ratios may be used to determine concentration levels. Figure 8 In the embodiment shown in , a first ratio R1 can be calculated based on the maximum / minimum values associated with oxygenated hemoglobin, and a second ratio R2 can be calculated based on the maximum / minimum values associated with deoxyhemoglobin. In this way, the measurement of the first ratio and the second ratio allows the two components of hemoglobin and their relative values to be distinguished. Multiple ratios can be used individually or in combination with each other to determine concentration levels. For example, a combination of ratios R1 and R2 can be used to determine the total concentration of hemoglobin (e.g., a combination of oxygenated hemoglobin and deoxyhemoglobin).
[0057] In one embodiment, determining one or more blood component concentration levels is performed locally by a medical device (e.g., an adherent device, an insertable device, etc.) In other embodiments, the measured amplitudes and / or ratios are transmitted to an intermediate device and / or a remote monitoring center, and the determination of the concentration levels is performed by the intermediate and / or remote monitoring center.
[0058] At step 708, the determined concentration level is stored and / or analyzed for use in detecting a patient condition. For example, in one embodiment, the determined concentration level (e.g., hemoglobin concentration level) is compared to a threshold level to detect a condition such as anemia. In some embodiments, the threshold level is an absolute value, while in other embodiments, the threshold level is initialized relative to the patient. For example, to calculate the initialized value, the concentration level may be determined during an initial period (via optical monitoring or via a blood test). After the initial value is determined, a threshold level is determined based on the initial value, and the threshold is used to detect a condition such as anemia.
[0059] As above relative to Figure 5 and Figure 6 As discussed, in some embodiments, storage of concentration levels and / or comparison of concentration levels to threshold levels to detect patient conditions is performed locally on a medical device (e.g., an adherent device, an insertable device, etc.). In other embodiments, storage of concentration levels and / or comparison of concentration levels to threshold levels to detect patient conditions is performed remotely at an intermediate device and / or a remote monitoring center. In response to a detected condition, such as anemia and / or other hemoglobin-related conditions, an alarm or warning may be generated and transmitted to the patient and / or a monitoring party (e.g., a physician, a hospital, etc.).
[0060] Fig. 9 is a diagram showing some embodiments (such as Figure 2CFlow chart of the steps for measuring hemoglobin concentration using two light sources and a single detector) according to the embodiment shown in FIG.
[0061] At step 900, a first light source is used to illuminate patient tissue at a first excitation wavelength. As discussed above, the excitation wavelength can be selected based on the blood component to be measured (i.e., the excitation wavelength is selected to generate an emission response with a desired morphology). To monitor blood component concentrations, the excitation wavelengths utilized are typically in the ultraviolet, visible, or infrared spectrum. When the first light source is turned on or illuminated, the second light source remains off, thereby causing only a single light source to illuminate at a given time.
[0062] At step 902, at least one photodetector is used to measure emission in response to a first excitation wavelength. Figure 5-Figure 8 In contrast to the embodiments described above, in some embodiments only a single emission wavelength is monitored. The emission wavelength utilized by the at least one light detector is selected to correspond to a known minimum and / or maximum of the emission response associated with the excitation wavelength of the first light source. As discussed above, the emission response can be the result of one or more of tissue absorbance, fluorescence, reflectance, etc., and the emission response morphology (e.g., amplitude measured at all wavelengths) is the result of the excitation wavelength provided by the first light source. Selecting the minimum / maximum along the emission response allows information about the blood component being analyzed to be determined without the need to monitor the entire spectrum of emission wavelengths.
[0063] As discussed above, the measurement collected at step 902 is a measurement of the intensity / amplitude of the emission response to the first excitation wavelength. The light detector responsible for measuring the amplitude at a particular emission wavelength converts the detected light into an electrical signal representative of the measured amplitude.
[0064] At step 904, a second light source is used to illuminate the patient tissue at a second excitation wavelength. As discussed above, the excitation wavelength can be selected based on the blood component to be measured (i.e., the excitation wavelength is selected to generate an emission response with a desired morphology). In order to monitor the concentration of blood components, the excitation wavelengths used are usually in the ultraviolet spectrum, the visible spectrum, or the infrared spectrum. However, both the first excitation wavelength and the second excitation wavelength must be unique in order to generate a unique emission response. When the second light source is turned on, the first light source is turned off, thereby making only a single light source emit light at a given time.
[0065] The excitation wavelength of the second light source is selected based on the blood component to be measured, so that the emission response provides the desired morphology. However, whereas the first excitation wavelength is selected to generate an emission response having a maximum value at the monitored emission wavelength, based on the concentration of the blood component to be measured, the second excitation wavelength is selected to generate an emission response that provides a value other than the maximum value at the monitored emission wavelength, preferably a minimum value.
[0066] At step 906, at least one photodetector is used to measure emission in response to the second excitation wavelength. In this embodiment, because it is the excitation wavelength that is modified, rather than the emission wavelength or the wavelength that is monitored, it is important that the emission wavelength monitored by the at least one photodetector is selected to correspond to a maximum value associated with the first excitation wavelength and to correspond to a minimum value or a value that is fairly close to the minimum value at the second excitation wavelength. In other embodiments, a second photodetector may be used to measure emission at the second wavelength. However, for Figure 8 For the purposes of the examples shown, only a single emission wavelength was measured.
[0067] At step 908, a ratio R is calculated based on the amplitude measured at the first emission wavelength measured in response to the first excitation wavelength and the amplitude measured at the first emission wavelength in response to the second excitation wavelength. As discussed above, the ratio represents the relationship between the amplitude measured relative to the maximum value of the emission response and the amplitude measured relative to the minimum value of the emission response. Utilizing this type of ratio allows external influences such as ambient light and noise to be minimized and allows accurate determination of blood component concentration levels without the need to monitor the entire spectrum of emission wavelengths.
[0068] Fig.10 is a flow chart illustrating long-term (eg, chronic) monitoring and storage of hemoglobin concentration and one or more physiological signals for use in detecting a patient condition.
[0069] At step 1000, a plurality of ratios are measured based on first amplitudes and second amplitudes measured by one or more photodetectors during a first monitoring period (e.g., an initialization period). A single light source may be utilized with a plurality of photodetectors associated with a plurality of emission wavelengths, or a light source at two or more excitation wavelengths may be utilized with one or more photodetectors associated with one or more emission wavelengths. In general, at least one of the emission wavelengths is selected to correspond to a maximum value of the emission response, and at least one of the emission wavelengths is selected to correspond to a minimum value of the emission response. This may be accomplished by appropriately selecting the emission wavelength(s) and / or appropriately selecting the excitation wavelength(s).
[0070] The initialization period requires a period of time long enough to determine a baseline for the blood concentration values to be monitored. This can mean several minutes of monitoring, or several days of monitoring. Multiple ratio measurements are collected during the monitoring period, allowing for averages and deviations associated with the blood concentration values to be monitored. The benefit of utilizing an initialization period is that measurements may differ between patients based on various factors, such as device placement, including general placement, and factors such as placement adjacent to blood vessels, patient's body type, skin color, etc. Each of these factors can modify the way light interacts with the patient and the resulting emission response from the patient.
[0071] In one embodiment, multiple unique ratios are collected to facilitate monitoring of different blood concentration levels (e.g., oxyhemoglobin, deoxyhemoglobin, etc.). For example, a first unique ratio may be associated with oxyhemoglobin, and multiple measurements may be collected during a first monitoring period relative to the first unique ratio at step 1000. A second unique ratio may be associated with a deoxyhemoglobin level, and multiple measurements may be collected during the first monitoring period relative to the second unique ratio at step 1000.
[0072] At step 1002, for each unique ratio value monitored, a plurality of ratio values corresponding to each unique ratio value measured during the first monitoring period are averaged to derive a personalized ratio value for the patient. For example, a plurality of ratio values associated with the oxyhemoglobin concentration levels collected during the initialization period are averaged and the averaged plurality of ratio values are used to generate a baseline or initial ratio value representing the average oxyhemoglobin level of the patient. The personalized ratio value may represent a true average of the oxyhemoglobin levels, an average of the monitored ratio values, or other statistical tools for determining one or more personalized ratio values.
[0073] At step 1004, the personalized ratio is used to set an alarm / warning threshold. In one embodiment, the threshold may be calculated at a predefined magnitude above and / or below the personalized ratio. For example, a personalized ratio regarding oxygenated hemoglobin concentration (e.g., oxygenated blood) may result in thresholds being set at fixed amounts above and below the personalized ratio, thereby creating a monitoring envelope around the personalized ratio. In other embodiments, the envelope is not defined by predetermined or fixed thresholds above and / or below the personalized ratio, but rather by statistical tools such as standard deviation. In other embodiments, the threshold is defined by a percentage change in the personalized ratio, and in other embodiments, the threshold may be defined by a rate of deviation from the personalized ratio (e.g., if the oxygenated hemoglobin level changes rapidly from the personalized ratio, the warning threshold is reached). For each personalized ratio monitored, a separate monitoring envelope may be created.
[0074] At step 1006, one or more ratios are monitored and compared to warning / alert thresholds for detecting patient conditions. The one or more ratios may be individual measurements or may be based on averages. For example, if the ratios for hemoglobin concentrations fall below a threshold, this indicates that the person may be anemic or experiencing blood loss and requires medical attention. In other embodiments, comparison values such as changes (e.g., percentage changes), rates of change, etc., from an initial value may be monitored.
[0075] At step 1008, in response to the monitored ratio exceeding one or more of the thresholds, or falling below one or more of the thresholds, an alarm is generated. In some embodiments, when a threshold is crossed, this triggers additional measurements to confirm the accuracy of the results. This may include increasing the frequency of taking readings, or simply continuing to monitor to ensure that the measured ratio is accurate.
[0076] The alarm can be provided to the patient in the form of an audio or visual alarm. The alarm can also be transmitted to the intermediate gateway 102 or the remote monitoring center 106 ( Figure 1 ). The alert may be provided to a physician or specialist for analysis and confirmation of the detected patient condition.
[0077] Combination of adhesive devices and / or plug-in devices relative to Fig.10 One of the benefits of the described embodiments is that they allow for long-term monitoring of trends in blood concentration levels. Specifically, utilizing the ratio minimizes the impact of external influences and noise (such as changes in ambient light conditions, etc.), and initializing the ratio to an average value monitored over an initial monitoring period allows for personalized ratios for each patient (to account for differences in each patient's physiology).
[0078] Fig.11 1 is a flow chart showing a method of dynamically monitoring and storing hemoglobin concentration and one or more physiological signals for detecting patient conditions. In this embodiment, one or more physiological parameters are measured and utilized to determine the patient state that triggers the measurement of one or more ratios of blood concentration levels.
[0079] At step 1100, one or more physiological parameters are monitored. Examples of monitored physiological parameters include ECG-related signals (eg, heart rate), bioimpedance, respiration rate, activity level, and / or posture.
[0080] At step 1102, the patient state is detected based on one or more physiological parameters. For example, the patient state may include heart-related patient states, such as various arrhythmia states (e.g., tachycardia, bradycardia, etc.), active or static states (based on posture, respiratory rate, heart rate, activity level, etc.), and the like. Depending on the detected patient state, it may be beneficial to monitor one or more ratios of one or more blood concentration levels (e.g., oxyhemoglobin, deoxyhemoglobin, etc.). For example, for patients with heart failure, it may be important to monitor the oxyhemoglobin level while the patient is exercising to ensure that it does not fall below a threshold level. One or more physiological signals are used to detect that the patient is exercising (e.g., based on one or more of posture, heart rate, respiratory rate, activity level, etc.). In response to the detected activity level, an optical signal is generated, and the emission is measured to calculate the ratio of the oxyhemoglobin concentration level. One of the benefits of increasing the level of optical monitoring or triggering optical monitoring based on the patient state is that resources (batteries, memory, processing bandwidth, data transmission, etc.) are saved until it is useful to monitor the patient state.
[0081] At step 1104, one or more excitation sources are used to illuminate the tissue, and one or more emission wavelengths are monitored for detecting one or more ratios related to one or more blood concentration levels.
[0082] At step 1106, a patient state is determined based on one or more measured ratios and one or more physiological parameters. For example, if it is determined that the patient is exercising, and the monitored ratio indicates that the oxyhemoglobin concentration has fallen below a threshold, this may indicate a dangerous condition for a patient suffering from heart failure. In response to detecting a condition such as this, at step 1108, an alarm is generated and provided to the patient. The alarm may indicate the detected condition, and instructions may be provided to the patient regarding risk mitigation. In other embodiments, the alarm may be transmitted to the intermediate device 102 and / or a remote monitoring center for review by a physician / technical expert.
[0083] Although the present invention has been described with reference to one or more exemplary embodiments, it will be appreciated by those skilled in the art that various changes may be made and elements thereof may be substituted with equivalents without departing from the scope of the present invention. In addition, many modifications may be made to adapt a particular situation or material to the teachings of the present invention without departing from its essential scope. Therefore, the present invention is not limited to the disclosed one or more specific embodiments, but the present invention will include all embodiments falling within the scope of the appended claims.
Claims
1. A system for non-invasively monitoring hemoglobin concentration levels, the system comprising: Medical equipment, the medical equipment comprising: at least one light source configured to provide light to patient tissue; a first light detector configured to monitor an emission response at a first emission wavelength, wherein the first emission wavelength is selected to correspond to a maximum of an emission response of a hemoglobin component; and a second photodetector configured to monitor the emission response at a second emission wavelength, wherein the second emission wavelength is selected to correspond to a minimum in the emission response of the hemoglobin component; and A processing module, the processing module being configured to: receiving an emission response at the first emission wavelength and an emission response at the second emission wavelength, calculating a ratio of a received emission response at the first emission wavelength to an emission response at the second emission wavelength, and The calculated ratio is used to determine the hemoglobin concentration level.
2. The system according to claim 1, characterized in that The hemoglobin component is oxyhemoglobin and the hemoglobin concentration level is an oxyhemoglobin concentration level, wherein the first emission wavelength is selected to correspond to a maximum value of an oxyhemoglobin emission response and the second emission wavelength is selected to correspond to a minimum value of the oxyhemoglobin emission response.
3. The system according to claim 1, characterized in that The hemoglobin component is deoxyhemoglobin and the hemoglobin concentration level is a deoxyhemoglobin concentration level, wherein the first emission wavelength is selected to correspond to a maximum value of a deoxyhemoglobin emission response and the second emission wavelength is selected to correspond to a minimum value of the deoxyhemoglobin emission response.
4. The system according to claim 1, characterized in that Further comprising a third light detector configured to monitor an emission response at a third emission wavelength, wherein the first emission wavelength is selected to correspond to a maximum of an oxyhemoglobin emission response, the third emission wavelength is selected to correspond to a maximum of a deoxyhemoglobin emission response, and the second emission wavelength is selected to correspond to an isosbestic point of the oxyhemoglobin emission response and the deoxyhemoglobin emission response.
5. The system according to any one of claims 1 to 4, characterized in that: The processing module is configured for controlling generation of an alarm in response to the hemoglobin concentration level falling below a threshold value, the hemoglobin concentration level falling below the threshold value indicating anemia or a change in the hemoglobin composition.
6. The system according to claim 1, characterized in that The hemoglobin concentration level is determined by the processing module in real time or near real time.
7. The system according to claim 1, characterized in that The processing module collects and stores a plurality of determined hemoglobin concentration levels over a first monitoring period and provides an output of trends in the monitored hemoglobin concentration levels.
8. The system according to any one of claims 1 to 4, characterized in that: The medical device further includes a sensor for monitoring physiological parameters associated with the patient, the physiological parameters including one or more of an electrocardiogram (ECG) signal, a respiration rate, a bioimpedance level, an activity level, a posture, and a temperature.
9. The system according to claim 8, characterized in that The processing module utilizes at least one of the monitored physiological parameters in combination with the stored hemoglobin concentration level to determine a patient condition.
10. A method for non-invasively monitoring hemoglobin concentration levels, the method comprising: providing incident light at a first excitation wavelength to tissue of a patient; monitoring an emission response at a first emission wavelength, wherein the first emission wavelength is selected to correspond to a maximum of an emission response of a hemoglobin component; monitoring the emission response at a second emission wavelength, wherein the second emission wavelength is selected to correspond to a minimum in the emission response of the hemoglobin component; and The hemoglobin concentration level is calculated based on a ratio of the emission response measured at the first emission wavelength to the emission response measured at the second emission wavelength.
11. The method according to claim 10, characterized in that The hemoglobin component is oxyhemoglobin and the hemoglobin concentration level is an oxyhemoglobin concentration level, wherein the first emission wavelength is selected to correspond to a maximum value of an oxyhemoglobin emission response and the second emission wavelength is selected to correspond to a minimum value of the oxyhemoglobin emission response.
12. The method according to claim 10, characterized in that The hemoglobin component is deoxyhemoglobin and the hemoglobin concentration level is a deoxyhemoglobin concentration level, wherein the first emission wavelength is selected to correspond to a maximum value of a deoxyhemoglobin emission response and the second emission wavelength is selected to correspond to a minimum value of the deoxyhemoglobin emission response.
13. The method according to claim 10, characterized in that Further comprising monitoring the emission response at a third emission wavelength, wherein the first emission wavelength is selected to correspond to a maximum of an oxyhemoglobin emission response, the second emission wavelength is selected to correspond to an isosbestic point of the oxyhemoglobin emission response and a deoxyhemoglobin emission response, and the third emission wavelength is selected to correspond to a maximum of a deoxyhemoglobin emission response.
14. The method according to claim 10, characterized in that Monitoring and calculating hemoglobin concentration levels are performed in real time or near real time.
15. The method according to any one of claims 10 to 14, characterized in that Further included is monitoring physiological parameters associated with the patient, the physiological parameters including one or more of an electrocardiogram (ECG) signal, a respiration rate, a bioimpedance level, an activity level, a posture, and a temperature.
